Vanda Pharmaceuticals (VNDA) is forecast to grow revenue at a rapid 22.7% per year, which is significantly higher than the broader US market's 10.2% growth rate. While the company remains unprofitable ...
5don MSN
Vanda narrows 2025 revenue guidance to $210M-$230M amid Fanapt growth and strategic investments
Discover Vanda Pharmaceuticals' Q3 2025 results: strong Fanapt growth, updated guidance, and pipeline milestones.
House Digest on MSN
Monopodial Vs Sympodial Orchids: Here's The Real Difference Between These Similar Flowers
The orchid family is one of the largest flowering plant categories of all time, but you really need to know the difference ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback